Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Older age, White race, APOE ε4 carrier, and diabetes were associated with biomarker levels indicative of higher AD risk (lower Aβ42/40; higher p-tau217, p-tau217/Aβ42, NfL, and GFAP). After adjustment for age, sex, race, education, body mass index, and estimated glomerular filtration rate, lower Aβ42/40, higher p-tau217, and higher p-tau217/Aβ42 were each associated with worse performance on processing speed and executive function (Figure 1). Higher NfL was associated with worse performance on all five domains, while higher GFAP was associated with worse performance on processing speed and verbal fluency. These associations remained significant after additional adjustment for APOE and cardiovascular risk factors, with no clear pattern for race interaction in biomarker-cognition associations. AD pathology and neurodegeneration indicated by blood biomarkers may already start contributing to cognitive function in midlife. Young and middle adulthood is a critical time for AD prevention, which may delay the onset of cognitive decline and dementia among middle-aged and older adults.

What this study adds

Evidence grade: Low

The record lists 1,356 participants. In midlife adults, blood markers indicating more Alzheimer's pathology and nerve injury were linked to worse performance on tests of processing speed, executive function and other thinking domains. The authors conclude that Alzheimer's-related processes may already affect thinking in midlife, making young and middle adulthood a critical time for prevention efforts.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jiang, X., Hoang, T. D. M., Shaw, L. M., Jacobs, D. R., Nasrallah, I. M., Bryan, R. N., et al. (2025). Alzheimer disease blood biomarkers and cognition in midlife. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_101201

Vancouver

Jiang X, Hoang TDM, Shaw LM, Jacobs DR, Nasrallah IM, Bryan RN, et al. Alzheimer disease blood biomarkers and cognition in midlife. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_101201. PMID: 41447483.

BibTeX

@article{jiang2025-41447483,
  author  = {Jiang, Xiaqing and Hoang, Tina Dan My and Shaw, Leslie M. and Jacobs, David R. and Nasrallah, Ilya M. and Bryan, R. Nick and Yaffe, Kristine S.},
  title   = {{Alzheimer disease blood biomarkers and cognition in midlife}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_101201},
  pmid    = {41447483},
  url     = {https://doi.org/10.1002/alz70856_101201}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In midlife adults, blood markers indicating more Alzheimer's pathology and nerve injury were linked to worse performance on tests of processing speed, executive function and other thinking domains. The authors conclude that Alzheimer's-related processes may already affect thinking in midlife, making young and middle adulthood a critical time for prevention efforts.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 1,356 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Kristine S. Yaffe: h-index 155 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41447483)
Free to read 2 / 2 Free to read
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →